Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Pfizer Inc.
Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.
ASCO: Transforming Treatment Paradigms in Renal Cell Carcinoma: Understanding the Role of Risk Stratification and Emerging Data in the Adjuvant Setting
Salon A-5 (Lower Level)
720 S Michigan Avenue
Chicago, IL 60605
What You'll Learn:
- The impact of recent data on current sequencing paradigms
- Single agent and combination strategies in the adjuvant setting
- How to weight toxicity management with treatment selection
Renal cell carcinoma (RCC) has been one of most difficult-to-treat of the solid tumors, and more recently, one of the most rapidly evolving fields in oncology. New data suggest impending changes to your practice in both early-stage and metastatic RCC, including novel indications, combination approaches, and optimized adjuvant strategies. The use of adjuvant therapy for RCC remains a hot topic for which high-quality, well-coordinated, multidisciplinary care is of utmost importance to achieving optimal outcomes in the perioperative setting for your patients with RCC.
In this program, a multidisciplinary panel of renowned experts in RCC will guide you through an in-depth, up-to-date review of risk assessment in the earlystage RCC setting, patient selection for adjuvant systemic therapy, evidence from clinical studies of adjuvant therapy for RCC, and overall multidisciplinary care planning. To help you apply this information and to provide you with opportunities to interact with the faculty and each other, this activity includes case-based discussions and a Medical Crossfire® debate on key areas of controversy and clinical uncertainty concerning the use of adjuvant therapy for RCC.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Pfizer Inc.
This educational program is directed toward urologists, medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of renal cell carcinoma. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with renal cell carcinoma will be invited to participate.
Upon completion of this activity, participants will be able to:
- Substantiate treatment decisions in the management of RCC at key decision points along the disease continuum based on the most pertinent clinical trial evidence for targeted therapy
- Integrate knowledge of patient selection and single-agent and combination strategies in the context of mechanisms of action, kinetics of response, best practices in monitoring, and key information that informs adjuvant treatment in the care of patients with renal cell carcinoma (RCC)
- Manage treatment-related toxicities as a component of therapeutic decision making in adjuvant treatment settings for patients with RCC
- Evaluate recent clinical trial data, key ongoing trials, and how emerging adjuvant strategies may further impact the RCC treatment landscape
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology/Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California
You must be logged in to PER to register for this meeting
Or Register for PER now